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to uniquely relate to plan quality. The quality of the plan
was strongly linked to satisfaction. CONCLUSIONS:
Overall, consumers rated the quality of their Rx plan as
high, were generally satisﬁed with their plans and ranked
the importance as high. The results indicate that plan
quality was dependent on satisfaction with out-of-pocket
payments. We also found that plan importance was pre-
dominately driven by consumer’s personal awareness of
the need for prescription medications. As consumer infor-
mation on Rx plans becomes more available, it is imper-
ative that information be presented in such a way as to
assist consumers in comparing and selecting appropriate
plans.
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OBJECTIVE: To investigate the market share of generics,
their production and promotion process by the Greek
pharmaceutical industry. METHODS: Analyses are based
on questionnaire mailed to companies members of the
Greek Federation of Pharmaceutical Companies, in 2002
with a response rate of 52%. Questionnaire was divided
in three sections, ﬁrst requested information on the com-
panies’ involvement in the production of generics, second
on companies’ opinion regarding generics characteristics
and government interventions, third on policies affected
generics demand. Data was analyzed in two stages, 
ﬁrst concerning detailed description of outcomes and
second percentage comparisons through binomial tests.
RESULTS: A total of 46.4% of the companies are
involved in the production and distribution of generics
while 53.6% are not, their difference is not statistically
signiﬁcant (equality of percentages test p = 0.59). The
mean period of companies involvement is 12 years while
80.8% of the respondents expressed positively for their
companies involvement in generics. A total of 30.8% of
the companies consider that the most important charac-
teristic of generics is that they are safe and cheap substi-
tutes of the brand drugs. Of the companies, 88.5%
consider government does not promote the prescription
of generics, whereas 11.5% had different opinion, bino-
mial test for the equality of percentages resulted in p <
0.001, meaning that the difference is statistically signiﬁ-
cant. The majority of companies (70.4%) consider that
cost-effectiveness analyses should be the criteria for inclu-
sion in the prescribed drug list vs. 18.5% the cost of treat-
ment, 3.7% for reference pricing and 3.7% for the daily
dose cost of treatment. Finally, majority of companies
consider the positive list as the most important factor for
the promotion of generics from health professionals.
CONCLUSION: Generics share in Greece is lower com-
pared to the EU countries. High share of imported brand
drugs, irrational pricing and parallel exports are main
factors contributing to continuing increase in drug expen-
diture and decrease in the drug production of Greek
industry.
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INTERVENTIONS AND COST SAVINGS
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Hsu C, Kuo H,Tai C
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OBJECTIVES: To demonstrate the impact of staff phar-
macists of interventions at a large (2389 beds), tertiary
care teaching hospital in Southern Taiwan. METHODS:
Based on the self-reported documentation made by phar-
macists during the conduct of routine dispensing activi-
ties in ambulatory and inpatient setting. Those intervened
suggestions were accepted by prescribing physicians. A
peer-review team decided the potential clinical signiﬁ-
cance of the self-reported documentation, and assessed
their cost savings results. Data collection period was from
January 1 to December 31, 2001. RESULTS: A total of
4424 interventions (94.8% of reported documentations)
by 25 pharmacists were analyzed. Of which, 59.4% of
these interventions were found to affect inappropriate
prescribing, 35.4% of these interventions were associated
with inappropriate drug utilization and the remaining
5.2% of interventions were drug interactions and mis-
cellaneousness. Six percent of reported documents were
evaluated in terms of direct cost savings (the difference 
in actual acquisition costs between prescriptions). Cost
savings were over $7400 and average $27 per interven-
tion for those sampled data. The most cost-saving 
interventions were related to incorrect quantity with the
indication, no indication, and improper concomitants/
duplication. CONCLUSIONS: The self-report documen-
tation tool in this constitute conﬁrms the potential to min-
imize the risks, cost saving and to improve hospital
prescribing associated with drug therapy.
PHP22
AN INVESTIGATION OF GENERIC DRUG
UTILISATION AND POTENTIAL SAVINGS FROM
GENERIC SUBSTITUTION IN THE IRISH
HEALTH CARE SETTING
Tilson L1, McGowan B1, Bennett K2, Ryan M1, Barry M1
1National Centre for Pharmacoeconomics, James’s St, Ireland;
2Trinity Centre for Health Sciences, Dublin, Ireland
OBJECTIVES: Expenditure on medicines continues to
increase signiﬁcantly in Ireland. Total payments to phar-
macies by the state for the year 2001 was €674.8 million,
a 27% increase as compared with the year 2000. Pre-
scribing less expensive generic preparations is one method
of reducing costs while maintaining therapeutic efﬁcacy.
While generic prescribing is encouraged, generic substi-
tution by pharmacists is not permitted. In this study the
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extent of generic drug utilisation for the two main drug
schemes, the General Medical Services (GMS) scheme and
the Drugs Payment (DP) scheme, was measured. Under
the GMS scheme, all prescribed drugs are fully reim-
bursement by the state. Under the DP scheme the pa-
tient pays up to €70/month for prescribed drugs and the
state pays the remainder. Potential savings from generic
substitution for both schemes were investigated.
METHODS: The cost and quantity of drugs dispensed in
2001 were analysed using a national primary care pre-
scribing database, which contains information on the
brand name, strength, form and cost of prescribed drugs.
Drugs are categorised into 4 classes on the database:
generic, branded generic, proprietary drug with a generic
equivalent, proprietary drug with no generic equivalent.
The analysis was performed using JMP and SAS (SAS
Institute Inc.). RESULTS: On the GMS scheme 22% of
prescription items were dispensed generically, whereas on
the DP scheme 12% were dispensed generically. On both
the GMS and DP schemes 18% of prescription items were
dispensed as a proprietary preparation when a generic
equivalent was available. Substitution of the cheapest
generic equivalent preparation would result in estimated
annual savings of €14.54 million (3.4% of total expen-
diture) on the GMS scheme and €4.88 million (2.7% of
total expenditure) on the DP scheme. CONCLUSIONS:
The results highlight the potential cost savings, which
could be made by generic substitution, facilitating the
most efﬁcient use of the limited drugs budget.
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OBJECTIVES: The objective of this study is to describe
the current state of Philippine drug prices across various
data sources. METHODS: Retail drug price data was
gathered for a list of the 124 pharmacologically active
ingredients most commonly reimbursed by PHIC. This
list was generated from a systematic sample of 410 claims
from a total 305,482 processed claims ﬁled at the
National Capital Region ofﬁce during the calendar year
2000. This sample also served as a source of national
drug price data. Other sources of price data included a
survey of international drug prices, and a joint Depart-
ment of Health-Management Sciences for Health drug
price survey from 64 points of sale throughout the
country. RESULTS: Data gathered from local sources 
displayed a large degree of variation. From the PHIC
processed claims sample, the average relative price dif-
ference between identical drug preparations was 382.7%
(SD ± 1080.3). Similarly, price data from the joint DOH-
MSH survey displayed an average relative price difference
of 247.4% (SD ± 538.4). Comparison of local to inter-
national price data showed that Philippine prices for
certain drug products may be 10–15 times higher than
those if purchased outside of the country. CONCLU-
SIONS: The results of this study substantiate the common
belief that there is extreme variation and inﬂation of drug
prices in the Philippines. Other related studies have also
shown that these considerable discrepancies cannot be
attributed wholly to the more common reasons for 
price variance such as transportation, purchasing power,
market ﬂuctuations, etc. This study’s ﬁndings also give
PHIC further license to develop an index of drug refer-
ence prices that will serve as a basis for drug reimburse-
ment in the hope of encouraging the more rational and
fair pricing of drugs.
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OBJECTIVES: To determine ﬁnancial and professional
beneﬁts to examinees for Board of Pharmceutical Spe-
cialties (BPS) certiﬁcation. METHODS: An anonymous
web-based survey was developed and pre-tested. The
survey was sent to all 84 US colleges of pharmacy. Demo-
graphics captured included college size, mean yearly
research dollars, faculty size, and enrollment. Information
regarding numbers of BPS-certiﬁed faculty, the extent to
which BPS certiﬁcation was considered in recruitment,
and compensation/incentives provided to faculty for cer-
tiﬁcation was obtained. RESULTS: Thirty-ﬁve surveys
were returned. Deans completed surveys (54%) and divi-
sion/ department chairs (43%). Mean number of full-time
faculty members/institution was 24 (range 9–60). Mean
number of full-time board certiﬁed faculty members was
7 (20%), with a range of 0–25. No institution required
board certiﬁcation for new faculty members; 8 (23%)
anticipated such a requirement for currently non-certiﬁed
faculty. Costs to examinees are estimated with minimum
and maximum expenses varied for test cases. The survey
revealed that expenses reimbursed varied considerably,
with 34% reimbursing no expenses, 34% reimbursing a
preparatory course and examination fee, 23% reimburs-
ing the examination fee only if the examinee is success-
ful, and 11% reimbursing travel expenses. The amount
of reimbursement was tabulated. While 66% of respon-
dents stated they encouraged faculty to seek board certi-
ﬁcation, fewer had faculty incentives. Only 17% provided
salary increases and 6% granted promotion to recognize
faculty members. Most institutions considered board cer-
tiﬁcation in promotion and tenure (66%) and provided
public recognition of successful examinees (51%). Poten-
tial values were attached to the promotion and tenure and
public recognition variables based on literature values.
CONCLUSIONS: BPS certiﬁcation is not required at this
